TORONTO, May 21, 2020 (GLOBE NEWSWIRE) — Datametrex AI Limited (the “Company” or “Datametrex”) (TSXV: DM, FSE: D4G, OTC: DTMXF) is pleased to announce that is has signed a Strategic Partnership and Development Agreement (the “Agreement”) with Transpharm Canada Inc. (“TCI”).
Under the term of the Agreement TCI will work with Datametrex on scoping out services and providing access to its 25,000 sq. ft state-of-the-art testing facility located in Toronto, ON, to provide support and testing services for COVID-19 testing kits that Datametrex has in its portfolio. Datametrex will be providing the COVID-19 test kits. TCI will be providing all other services including but not limited to the collection of specimens, transport of specimens, and processing test results.TCI will design, engineer, and develop a fully integrated suite of testing systems that will include in the field and lab testing protocols using TCI’s fully compliant Health Canada licensed Good Manufacturing Practice (“GMP”) manufacturing and testing facility. TCI lab has a current capacity to process 2,304 nucleic acid COVID-19 real-time detection kits (the “Kits”) every 24 hrs using CFX96 real-time PCR detection system machines and is scalable to over 10,000 test kits every 24 hrs.Transpharm will develop a Point of Care Diagnostic Kit System (the “TCI System”) with clear protocols of specimen collection, specimen handling, and specimen container labeling including the patient’s full name, date of collection, and one other unique identifier such as date of birth or government issued health card number. Transpharm will also develop a procedure focused around delivery related to specimen transport media tube protocols including to ensure cap on tube is tightly sealed, shipped at 2-8°C, 26-46°F to the TCI laboratory testing facility.Datametrex is committed to helping Canada and Canadians find a safe and secure way to get people out of lockdown and back to work. The Company first identified the need for high quality test kits back in April, since then, it has established relationships with four South Korean manufacturers of nucleic acid test kits. The Company quickly identified that both public and private corporations are not fully equipped to administer and process the test kits on their own. As a result, the Company quickly sourced a qualified lab testing company to partner with that will provide customers with a turnkey solution to administer tests efficiently, safely, and accurately. The Company believes testing is going to be key to re-opening the economy in a safe fashion, and also believes in providing Canadians with the best solution. “By participating in this project, Datametrex reaffirms its commitment to helping it customers, shareholders, families, and the Canadian public. This project hopes to aid in the reopening of businesses, travel, places of worship, community spaces, and social and cultural events in a safe and economic way,” said Marshall Gunter, CEO of Datametrex.Dr. Alexander MacGregor, founder and President of TCI, stated, “Transpharm is pleased to join in the COVID-19 fight with Datametrex and provide a world class testing facility for this endeavour. This world pandemic poses an unprecedented threat to the way that most people live their daily lives. There are several obvious steps we can take to ensure that no one must choose between their health and leaving their homes, and that begins with testing. Transpharm has the people, the equipment, and world class lab space to meet the enormous demand coming and to get the job done.”About Transpharm Canada IncTranspharm Canada Inc. provides pharmaceutical education, technology, and research opportunities to students through its subsidiary, Toronto Institute of Pharmaceutical Technology, North America’s premier pharmaceutical training institute. The facility is also fully compliant Health Canada licensed Good Manufacturing Practice (“GMP”) manufacturing and testing facility and is a full-service clinical development business that provides clinical trial services to biotechnology companies. Additional information on TIPT is available at www.tipt.comAbout DatametrexDatametrex AI Limited is a technology focused company with exposure to Artificial Intelligence and Machine Learning through its wholly owned subsidiary, Nexalogy (www.nexalogy.com).Additional information on Datametrex is available at www.datametrex.comFor further information, please contact:Marshall Gunter – CEO
Phone: (514) 295-2300
Email: firstname.lastname@example.orgNeither the TSX Venture Exchange nor it’s Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this releaseForward-Looking StatementsThis news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy.Readers are cautioned to consider these and other factors, uncertainties, and potential events carefully and not to put undue reliance on forward-looking information. The forward-looking information contained herein is made as of the date of this press release and is based on the beliefs, estimates, expectations, and opinions of management on the date such forward-looking information is made. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.
Tempus Launches COVID-19-Specific Clinical and Research Initiatives for Oncology
CHICAGO, May 30, 2020 (GLOBE NEWSWIRE) — Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, introduced a series of offerings designed to both advance vital research and support physicians in treating cancer patients, despite the challenges of the COVID-19 pandemic. Tempus is equipping physicians with the tools they need to treat high-risk patients while limiting their exposure to the virus, with mobile phlebotomy services, on-demand virtual case reviews, and COVID-19 PCR diagnostic testing for cancer patients.
“Cancer continues to be among the leading causes of death worldwide, and now more than ever, it is critical that cancer patients continue to receive the care and treatment they need for survival despite the pandemic,” said Eric Lefkofsky, Founder and CEO. “In the last few months, we’ve quickly mobilized to create offerings that ease the burden on physicians treating cancer patients amidst the threat of COVID-19, through a series of services and tests that are badly needed to ensure therapies aren’t disrupted.”COVID-19 PCR Diagnostic Testing
Earlier this month, Tempus launched a diagnostic polymerase chain reaction (PCR) test for COVID-19. Tempus’ CAP-accredited/CLIA-certified labs in Chicago and Atlanta are supporting the acceleration of testing in the U.S., and expect to test approximately 12,000 patients daily across both labs, with the ability to scale further if needed. Tempus makes it seamless for physicians to test their patients for the virus, providing results within 24-48 hours at no cost to the patient as Tempus bills insurance directly. Mobile Phlebotomy
Tempus now offers mobile phlebotomy services, which are available to patients who require a blood draw but are too sick or unable to travel to the clinic, or do not have access to an in-office phlebotomist or draw site. Experts are able to perform blood draws in patients’ homes for any Tempus test in which a blood sample is required, at no added cost.Virtual Case Reviews
Tempus’ on-demand virtual case review system provides clinical support to physicians and care teams in a timely manner when an in-person meeting isn’t possible. Tempus’ Medical Affairs team is available to answer patient report questions in real-time in a secure portal. In addition, Tempus now offers a variety of tele-health support services specific to COVID-19 if needed.Research Collaboration
Tempus has launched a large research collaboration to structure data for up to 50,000 COVID-19 positive patients. As part of the IRB approved study, Tempus is partnering with providers to collect data on COVID-19 patients, which Tempus is structuring and de-identifying without cost. In addition, Tempus expects to perform full transcriptomic profiling of approximately 10,000 patients within the cohort. All data will be shared with all participating institutions without restriction. About Tempus
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of clinical and molecular data, and an operating system to make that data accessible and useful, Tempus enables physicians to make real-time, data-driven decisions to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.Erin Carron
Tempus’ TIME Trial™ Program Reaches Critical Scale and Operational Milestones
CHICAGO, May 29, 2020 (GLOBE NEWSWIRE) — Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, has reached a milestone in fully enrolling 2,500 oncologists into its Tempus Integrated Molecular Evaluation (TIME) Trial™ Program that seeks to rapidly match patients largely in the community setting to targeted clinical trials. To date, Tempus has signed up over 50 provider networks, over 30 unique biomarker trials, and has rapidly opened sites onto trials in an average of 10 days. Through the TIME Trial™ Program, Tempus is bringing the very best clinical trials to communities across the country, giving thousands of patients access to novel therapeutics.
“We have experience with clinical trial rapid deployment models, however Tempus provides an unparalleled level of commitment and support in aligning all involved parties and streamlining the process, especially given the challenges of the COVID-19 pandemic,” said Dr. Julio Peguero, Director of Research of Oncology Consultants. “We ultimately met our target goal of activating this trial in just two weeks, and hope to do the same for future patients.”Last spring, Tempus launched the TIME Trial™ Program in an effort to increase clinical trial participation by using real-time clinical and molecular data to match patients to trials, and then rapidly open pre-qualified sites once a patient has been identified. Since then, Tempus has built its TIME Trial™ Network, inclusive of some of the country’s top community hospitals and academic medical centers, totaling over 50 research sites and 2,500 oncologists.As of today, the program has 30 pharma-sponsored clinical trials, covering dozens of unique, actionable biomarkers across both solid and hematological malignancies. Every week, Tempus screens thousands of new patients against the criteria of the ultra-rare trials in the TIME Trial™ Network. Thus far, Tempus has matched nearly 1,000 patients to the trials in its portfolio and averaged just under 10 days from patient screened to site activated.“Cutting-edge cancer therapies increasingly target narrower populations of patients, and the clinical trials that study these therapies require equally specific patient populations,” said Amy Franzen, Vice President of Operations and Program Lead. “Tempus is able to use its advanced technology, access to real-time data, and strong operations to get the right patients access to the right therapies, closer to home.”Tempus screens patients from sites in the TIME Trial™ Network against applicable inclusion/exclusion criteria utilizing genomic sequencing data, matched with the patients’ clinical data. Then, Tempus applies its computational algorithm to provide rapid, comprehensive matches to applicable trials that can be brought to the patient. Once a patient has been screened and matched, Tempus provides the patient’s physician with a report that ranks relevant trials. If the physician expresses interest in enrolling his or her patient in a trial, the Site and Sponsor leverage a standard contract, standard rate card, and a central IRB to rapidly open the clinical trial and enroll the patient into the study in under two weeks.For the same reason that precision medicine is now possible due to technological advances such as cost effective genomic sequencing at scale, the maturing of artificial intelligence, and the evolution of cloud technology, it is now possible to run clinical trials more efficiently and based on real-time data. Tempus is increasing the speed of clinical trials and reaching into community settings, where the majority of cancer patients are treated today.About Tempus
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of clinical and molecular data, and an operating system to make that data accessible and useful, Tempus enables physicians to make real-time, data-driven decisions to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.
Completely Online Summer Math Camps Offered to Meet Strong Demand from Parents During COVID-19
San Diego, May 29, 2020 (GLOBE NEWSWIRE) — Parents looking for a summer camp this year may find that there are limited options due to COVID-19 social distancing guidelines. Art of Problem Solving (AoPS), a leader in math education that has prepared hundreds of thousands of students for some of the most prestigious universities, has transformed its Summer Camp activities online to create a collaborative learning and social space for children in third grade through high school. The Summer Camp activities help students develop problem solving skills through group activities in math and related subjects.Though this is the fourth year that Art of Problem Solving has offered a Summer Camp, this is the first time the organization is offering the camp experience completely online. Activities include learning how to develop cryptographic skills to protect internet security, to a class that integrates math learning as part of a poetry project that concludes with a Poetry Slam. The two-week and four-week sessions start in June and last through the summer.“As a result of the COVID-19 pandemic, many parents are seeking a summer camp experience for their children that conforms to social distancing norms while encouraging learning and collaboration,” said Richard Rusczyk, the founder of Art of Problem Solving, which has offered classes since 2003. “At Art of Problem Solving, we quickly adapted our on-campus Summer Camp experience with our online academic models. Our first-ever online Summer Camp is designed to encourage students to develop problem solving skills in a personalized and collaborative group environment.”The COVID-19 pandemic has created wider public awareness of the relevancy of math and statistics in everyday life. Rusczyk said his organization has seen that interest reflected in demand from more parents and children who see math skills as increasingly important. Also, in response to COVID-19, the company offered for a limited time a free trial to its Beast Academy program that integrates comic-style “beast” characters and exercises, puzzles and games.The Art of Problem Solving began in 1993 with a pair of textbooks for middle and high school math contest participants. Ten years later, Art of Problem Solving launched a website with an online school and full math curriculum designed for high-performing math learners. Every member of the 2015, 2016, 2018, and 2019 U.S. International Math Olympiad teams―each of which took first place in the competition―are Art of Problem Solving alumni who collectively participated in more than 110 Art of Problem Solving Online courses. The Art of Problem Solving is an ACS WASC Accredited School that offers programs online and, prior to COVID-19, at its nationwide campus locations. The organization also works with school districts to integrate their offerings as part of school math lessons.Looking beyond the immediate pandemic, problem solving skills are considered to be essential to the nation’s future workforce. As professions shift toward greater use of automation and artificial intelligence, there is expected to be an increased demand for people who have the ability to identify creative solutions and manage these developments. Critical thinking and problem solving is a top skill identified by National Association of Colleges and Employers.About Art of Problem SolvingArt of Problem Solving has successfully trained hundreds of thousands of motivated students in preparation for success at top-tier colleges and careers. Through rigorous, high-quality K-12 math curriculum, online classes and learning centers, Art of Problem Solving trains today’s brightest minds to solve tomorrow’s challenges. For additional information, visit www.artofproblemsolving.com.Jaclyn Walian
Latest News11 months ago
Bleckwen Raises $10m and Appoints David Christie as CEO
Artificial Intelligence1 year ago
Kneron Debuts Edge AI Chip, Bringing AI to Devices Everywhere
Artificial Intelligence1 year ago
Chartis Research Names FICO a Category Leader in AI for Financial Services
Artificial Intelligence12 months ago
LogRhythm Scores the Singapore Business Review Technology Excellence Award 2019 for Cyber Security – Computer Software
Artificial Intelligence1 year ago
CredoLab extends smartphone-based scoring to insurers
Artificial Intelligence1 year ago
Tuya Exhibiting Products from its Global Clients that are “Powered by Tuya”
Artificial Intelligence12 months ago
Chengdu Tianfu Software Park Reflects the Vitality of IP Innovation
Artificial Intelligence8 months ago
Mogo announces a digital lending pilot with goeasy Ltd.